Literature DB >> 23524987

Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation.

Craig I Coleman1, Stacey M Coleman, Julie Vanderpoel, Winnie Nelson, Jennifer A Colby, Jennifer M Scholle, Jeffrey Kluger.   

Abstract

OBJECTIVE: To compare patient-reported limitations, concerns, and burdens in those receiving and not receiving warfarin for thromboprophylaxis in atrial fibrillation (AF).
METHODS: We conducted a cross-sectional survey study of patients with AF receiving thromboprophylaxis for stroke prevention. Patients were administered the validated Anti-Clot Treatment Scale (ACTS). Mean scores of patients receiving and not receiving warfarin were compared for each ACTS item, and for the Burden and Benefit subscales.
RESULTS: From July 2010 to August 2011, 80 patients with AF were administered the survey, with 65 patients receiving a regimen containing warfarin and 15 patients not receiving a regimen containing warfarin. Six of the 17 individual questions depicting patient- perceived limitations in physical activity due to bleeding, limitations on diet, feelings of inconvenience of occasional aspects of thromboprophylaxis therapy, and frustration, and burden had less favorable scores in the warfarin-managed patients compared with the patients not receiving warfarin (P < 0.05 for all). Mean ACTS Burden scores were more favorable in the no-warfarin group (44.5 ± 6.4) compared with the warfarin group (39.8 ± 8.0; P = 0.003). No difference was seen between the 2 groups on the ACTS Benefits score (11.1 ± 3.4 vs 10.4 ± 3.7; P = 0.38).
CONCLUSION: Patients with AF receiving warfarin may have less favorable feelings regarding thromboprophylaxis versus those receiving non-warfarin thromboprophylaxis. Patients report having more limitations and having greater feelings of burden on warfarin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524987     DOI: 10.2310/JIM.0b013e31828df1bf

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  10 in total

1.  Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®.

Authors:  Miguel A Ruiz; José Ramón González-Porras; José Luis Aranguren; Eduardo Franco; Fernando Villasante; José Tuñón; Tomás José González-López; Marina de Salas-Cansado; Javier Soto
Journal:  Qual Life Res       Date:  2016-12-18       Impact factor: 4.147

Review 2.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

3.  Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.

Authors:  Craig I Coleman; Muralikrishna Tangirala; Thomas Evers
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

Review 4.  Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.

Authors:  Jeff R Schein; C Michael White; Winnie W Nelson; Jeffrey Kluger; Elizabeth S Mearns; Craig I Coleman
Journal:  Thromb J       Date:  2016-06-13

Review 5.  Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence.

Authors:  Kristine C Willett; Amanda M Morrill
Journal:  Ther Clin Risk Manag       Date:  2017-04-06       Impact factor: 2.423

6.  Satisfaction with oral anticoagulants in patients with atrial fibrillation.

Authors:  Carmen Suárez Fernández; Luis Castilla-Guerra; Jesus Cantero Hinojosa; Josep Maria Suriñach; Fernando Acosta de Bilbao; Juan José Tamarit; José Luis Diaz Diaz; Jose Luis Hernandez; Antonio Pose; Manuel Montero-Pérez-Barquero; Jaume Roquer; Jaime Gállego; José Vivancos; Jose María Mostaza
Journal:  Patient Prefer Adherence       Date:  2018-02-19       Impact factor: 2.711

7.  Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).

Authors:  Dragos Vinereanu; Dmitry Napalkov; Jutta Bergler-Klein; Bela Benczur; Martin Ciernik; Nina Gotcheva; Alexey Medvedchikov; Pentti Põder; Dragan Simic; Andris Skride; Wenbo Tang; Maria Trusz-Gluza; Jiri Vesely; Tatiana Vishnepolsky; Mirej Vrabec
Journal:  Open Heart       Date:  2020-03-24

8.  Satisfaction With Oral Anticoagulants Among Patients With Atrial Fibrillation: A Prospective Observational Study.

Authors:  Shahrzad Salmasi; Adenike Adelakun; Abdollah Safari; Leanne Kwan; Jenny MacGillivray; Jason G Andrade; Marc W Deyell; Anita Kapanen; Peter Loewen
Journal:  CJC Open       Date:  2021-06-29

9.  Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.

Authors:  Craig I Coleman; Sylvia Haas; Alexander G G Turpie; Silvia Kuhls; Susanne Hess; Thomas Evers; Pierre Amarenco; Paulus Kirchhof; A John Camm
Journal:  Clin Cardiol       Date:  2016-06-30       Impact factor: 2.882

10.  Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.

Authors:  Leo Ungar; Fatima Rodriguez; Anne S Hellkamp; Richard C Becker; Scott D Berkowitz; Guenter Breithardt; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Christopher C Nessel; Daniel E Singer; Manesh R Patel; Jonathan P Piccini; Kenneth W Mahaffey
Journal:  Cardiol Ther       Date:  2019-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.